Article
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.
Hepatology (Baltimore, Md.) - 1 Oct 2007
Jacobson Ira M, Brown Robert S, McCone Jonathan, Black Martin, Albert Clive, Dragutsky Michael S, Siddiqui Firdous A, Hargrave Thomas, Kwo Paul Y, Lambiase Louis, Galler Greg W, Araya Victor, Freilich Bradley, Harvey Joann, Griffel Louis H, Brass Clifford A
Abstract excerpt
UNLABELLED: WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in treatment-naive patients with chronic hepatitis C and compensated liver disease....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.